Scarica l'app Stockscreener
1.28
5.88%
-0.08
Pre-mercato:
1.28
Precedente Chiudi:
$1.36
Aprire:
$1.42
Volume 24 ore:
68,561
Relative Volume:
1.03
Capitalizzazione di mercato:
$2.48M
Reddito:
-
Utile/perdita netta:
$-9.32M
Rapporto P/E:
-0.1007
EPS:
-12.7107
Flusso di cassa netto:
$-7.30M
1 W Prestazione:
-12.33%
1M Prestazione:
-10.49%
6M Prestazione:
-46.67%
1 anno Prestazione:
-81.65%
Intervallo 1D:
$1.28
$1.42
Intervallo di 1 settimana:
$1.20
$1.65
Portata 52W:
$1.20
$7.461
Tharimmune Inc Stock (THAR) Company Profile
Nome
Tharimmune Inc
Settore
Industria
Telefono
302-743-2995
Indirizzo
1200 ROUTE 22 EAST, BRIDGEWATER
Confronta THAR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
1.28 | 2.48M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Tharimmune Inc Borsa (THAR) Ultime notizie
THAR stock touches 52-week low at $1.2 amid sharp annual decline By Investing.com - Investing.com South Africa
Jayud Global Logistics Ltd (JYD): What Makes The Stock Good? - Marketing Sentinel
THAR stock touches 52-week low at $1.2 amid sharp annual decline - Investing.com
Tharimmune Says FDA Requires No Additional Trials of TH104 Against Opioid Exposure - MarketScreener
FDA greenlights Tharimmune’s drug application pathway - Investing.com India
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure - standard-journal.com
FDA Fast-Tracks Tharimmune's Revolutionary Opioid Defense Drug: No Clinical Trials Needed - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha - Weatherford Democrat
Game-Changing Oral Alternative to Injectable Antibody Achieves Key Milestone - Stock Titan
Tharimmune leverages Epiclick platform to expand pipeline - BioWorld Online
Hillstream Biopharma stock hits 52-week low at $1.36 - Investing.com
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology - Markets Insider
Tharimmune unveils novel cancer treatment HS1940 - Investing.com India
Tharimmune unveils novel cancer treatment HS1940 By Investing.com - Investing.com South Africa
Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Declines By 58.6% - Defense World
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Tharimmune appoints new CFO following resignation By Investing.com - Investing.com Canada
Tharimmune Says Thomas Hess Resigns As CFO -February 27, 2025 at 05:34 pm EST - Marketscreener.com
Tharimmune Says Thomas Hess Resigns As CFO - TradingView
Tharimmune appoints new CFO following resignation - Investing.com
Hillstream Biopharma stock hits 52-week low at $1.83 By Investing.com - Investing.com Canada
Hillstream Biopharma stock hits 52-week low at $1.83 - Investing.com
Financial Analysis: ObsEva (NASDAQ:OBSV) & Tharimmune (NASDAQ:THAR) - Defense World
Comparing Tharimmune (NASDAQ:THAR) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Tharimmune (NASDAQ:THAR) and Cara Therapeutics (NASDAQ:CARA) Head-To-Head Review - Armenian Reporter
Comparing Cara Therapeutics (NASDAQ:CARA) & Tharimmune (NASDAQ:THAR) - Defense World
Larchmont broker accused of years-long insider trading scheme - Westfair Communications
Tharimmune (NASDAQ:THAR) Trading 3% Higher – Should You Buy? - Defense World
Tharimmune to Present at the Microcap Conference 2025 - Bellingham Herald
Tharimmune to Present at Microcap Conference 2025, Showcase Growth Strategy - StockTitan
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting - ACCESS Newswire
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis - ACCESS Newswire
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - ACCESS Newswire
tharimmune CEO Randy Milby buys shares worth $9,752 - Investing.com India
tharimmune CEO Randy Milby buys shares worth $9,752 By Investing.com - Investing.com Canada
Tharimmune files to sell 1.44 million shares of common stock by selling shareholders - MSN
Tharimmune, Inc. Appoints Sanam Parikh to Its Board of Directors - Marketscreener.com
Tharimmune plans Phase 2 trial for itch treatment TH104 - Investing.com
Tharimmune plans Phase 2 trial for itch treatment TH104 By Investing.com - Investing.com UK
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update - Eagle-Tribune
Tharimmune Advances TH104 Clinical Program: Phase 2 Trial Set for 2025 After Positive Phase 1 Results - StockTitan
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.55% - MSN
Tharimmune announces $2.02M private placement; shares up - MSN
Tharimmune (NASDAQ:THAR) Coverage Initiated at Rodman & Renshaw - Defense World
Rodman & Renshaw Initiates Coverage of Tharimmune (THAR) with Buy Recommendation - MSN
Tharimmune secures $2.02 million in private funding By Investing.com - Investing.com Nigeria
THARTharimmune, Inc. Latest Stock News & Market Updates - StockTitan
Tharimmune Inc Azioni (THAR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.89%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):